Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2Phase NA 1

Status

Completed 2Withdrawn 1Terminated 1Active not recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 1

Conditions

Neoplasms 1331Breast Neoplasms 688Carcinoma, Non-Small-Cell Lung 543Neoplasm Metastasis 437Lymphoma 435Leukemia, Myeloid, Acute 432Melanoma 402Prostatic Neoplasms 380Multiple Myeloma 366Lymphoma, Non-Hodgkin 356Ovarian Neoplasms 343Colorectal Neoplasms 333Precursor Cell Lymphoblastic Leukemia-Lymphoma 328Pancreatic Neoplasms 328Leukemia, Lymphocytic, Chronic, B-Cell 323Leukemia 282Lung Neoplasms 275Glioblastoma 267Unspecified Adult Solid Tumor, Protocol Specific 257Recurrence 254Lymphoma, Follicular 248Lymphoma, Large B-Cell, Diffuse 245Brain Neoplasms 232Lymphoma, Mantle-Cell 210Hodgkin Disease 193Carcinoma, Renal Cell 193Head and Neck Neoplasms 192Myelodysplastic Syndromes 187Glioma 172Burkitt Lymphoma 172

Interventions

Taxes 1Paclitaxel 1Dasatinib 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Completed × Carcinoma, Endometrioid × Clear all
NCT03748186 2025-08-20

Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers

Sutro Biopharma, Inc.

Phase 1 Completed
136 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Carcinoma, Endometrioid

NCT01440998 2018-04-05

Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer

National Cancer Institute (NCI)

Phase 1 Completed
18 enrolled

Carcinoma, Endometrioid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡